Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease.

Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, Kulic L, Cvetanovska G, Blom H, Stoffel-Wagner B, Kölsch H, Weller M, Jessen F.

Neurodegener Dis. 2010;7(6):373-8. doi: 10.1159/000309657. Epub 2010 Jun 3.

2.

Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.

Arlt S, Schwedhelm E, Kölsch H, Jahn H, Linnebank M, Smulders Y, Jessen F, Böger RH, Popp J.

J Alzheimers Dis. 2012;31(4):751-8. doi: 10.3233/JAD-2012-112138.

PMID:
22710910
3.

A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.

Connelly PJ, Prentice NP, Cousland G, Bonham J.

Int J Geriatr Psychiatry. 2008 Feb;23(2):155-60.

PMID:
17600848
4.

Impacts of hyper-homocysteinemia and white matter hyper-intensity in Alzheimer's disease patients with normal creatinine: an MRI-based study with longitudinal follow-up.

Huang CW, Chang WN, Lui CC, Chen CF, Lu CH, Wang YL, Chen C, Juang YY, Lin YT, Tu MC, Chang CC.

Curr Alzheimer Res. 2010 Sep;7(6):527-33.

PMID:
20455861
5.

Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.

Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr.

Neurology. 1998 Jan;50(1):164-8.

PMID:
9443474
6.

Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.

Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M.

Neurosci Lett. 1999 May 21;267(1):65-8.

PMID:
10400250
7.

Association of RFC1 A80G and MTHFR C677T polymorphisms with Alzheimer's disease.

Bi XH, Zhao HL, Zhang ZX, Zhang JW.

Neurobiol Aging. 2009 Oct;30(10):1601-7. doi: 10.1016/j.neurobiolaging.2007.12.010. Epub 2008 Feb 6.

PMID:
18258338
8.

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study.

Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, Kervinen K, Kesäniemi YA, Riekkinen PJ, Laakso M.

BMJ. 1997 Oct 25;315(7115):1045-9.

9.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
10.

S-adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine are not related to folate, cobalamin and vitamin B6 concentrations.

Becker A, Smulders YM, Teerlink T, Struys EA, de Meer K, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.

Eur J Clin Invest. 2003 Jan;33(1):17-25.

PMID:
12492448
11.

Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease.

Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW.

Biol Psychiatry. 1999 Feb 15;45(4):422-5.

PMID:
10071711
13.
14.

Methylenetetrahydrofolate reductase gene and risk of Alzheimer's disease in Koreans.

Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Shin HY, Yoon JS.

Int J Geriatr Psychiatry. 2008 May;23(5):454-9.

PMID:
17932993
15.

Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.

Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):720-6. doi: 10.1002/ajmg.b.30668.

PMID:
18163432
16.

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.

Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.

PMID:
9850873
17.

The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.

Martínez MF, Martín XE, Alcelay LG, Flores JC, Valiente JM, Juanbeltz BI, Beldarraín MA, López JM, Gonzalez-Fernández MC, Salazar AM, Gandarias RB, Borda SI, Marqués NO, Amillano MB, Zabaleta MC, de Pancorbo MM.

BMC Neurosci. 2009 Sep 30;10:125. doi: 10.1186/1471-2202-10-125.

18.

Alzheimer's disease and total plasma aminothiols.

McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B.

Biol Psychiatry. 2003 Feb 1;53(3):254-60.

PMID:
12559659
19.

Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls.

Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T.

J Alzheimers Dis. 2009;18(2):331-7. doi: 10.3233/JAD-2009-1146.

PMID:
19584438
20.

[Plasma, red cell, and cerebrospinal fluid folate in Alzheimer's disease].

Abalan F, Zittoun J, Boutami C, Dugrais G, Manciet G, Decamps A, Antoniol B.

Encephale. 1996 Nov-Dec;22(6):430-4. French.

PMID:
10901835

Supplemental Content

Support Center